ArticleCureus2026
The Safety and Effectiveness of Root ZX3 for Symptomatic Irreversible Pulpitis: A Protocol for a Single-Center, Open-Label, Single-Arm Clinical Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Root ZX3, a high-frequency dental generator introduced in 2021, utilizes high-frequency current (HFC) within the root canal to coagulate and incinerate pulp tissue in seconds. Despite its clinical potential, evidence regarding its specific application for symptomatic irreversible pulpitis (SIP) remains scarce. This study aims to evaluate the safety and clinical effectiveness of Root ZX3 for the management of SIP in a dedicated clinical trial. Specifically, the primary objective is to assess the immediate relief of spontaneous pain (primary endpoint) and the incidence of adverse events following HFC application. Methods In this single-center, single-arm trial, we will include 10 permanent teeth diagnosed with SIP. Following infiltration anesthesia and dental dam isolation, an access cavity will be prepared to allow the Root ZX3 tip electrode to contact the pulp tissue. After the HFC application, the cavity will be sealed with a temporary restoration. Our primary endpoint is the resolution of spontaneous pain on postoperative day 0, defined as the proportion of participants achieving complete relief. Discussion SIP-related emergencies often disrupt clinical workflows due to their unscheduled nature. The treatment time is a critical bottleneck in these scenarios. By employing Root ZX3, clinicians may manage SIP more efficiently without increasing chair time or affecting other patients. If this protocol proves effective and safe, Root ZX3 will offer a valuable technical alternative for the immediate management of acute pulpitis. Conclusion This clinical trial will provide the first systematic evaluation of the Root ZX3's HFC application for managing SIP. By leveraging its ability to rapidly coagulate pulp tissue in anatomically complex areas, this approach aims to streamline the emergency endodontic workflow without compromising patient safety or treatment precision. Although this exploratory study is limited by its single-center design and small cohort, the results are expected to provide a critical foundation for optimizing pain-relief protocols. Ultimately, demonstrating the effectiveness of Root ZX3 could establish it as a valuable, time-efficient option for the immediate relief of acute pulpal pain in busy clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.